Nobuhiro Fujiyama

Dr. Nobuhiro Fujiyama

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2007 in Biological and Pharmaceutical Bulletin
Verified
Journal Article
Open access
PDF file
NFNobuhiro Fujiyama
Nobuhiro Fujiyama
YSYoshihisa Shitara
Yoshihisa Shitara
KIKousei Ito
Kousei Ito
YMYasuhiro Masubuchi
Yasuhiro Masubuchi
THToshiharu Horie
Toshiharu Horie
Previous reports have demonstrated that an intestinal injury causes hypofunctions of the liver associated with down-regulations of cytochrome P450, but an influence on hepatic transporters remains unclear. Here, we tested hepatic transporter functions in a rat model of bowel injury using indomethacin (IDM). After administration of IDM (8.5 mg/kg, i.p., 3 d), the rats suffered the intestinal impairment indicated by a reduction of alkaline phosphatase activity in mucosa. In vivo pharmacokinetic experiments of bromosulfophthalein (BSP) showed that there was a reduction in its plasma elimination rate and cumulative biliary excretion in IDM-treated rats and systemic and biliary clearances reduced to nearly 50% of the control group. Protein expressions in plasma membrane and mRNA levels of organic anion transporting polypeptide 1b2 (Oatp1b2) and multidrug resistance-associated protein 2 (Mrp2), which play hepatic BSP uptake and biliary excretion, respectively, in the liver were significantly reduced following the IDM treatment. In portal plasma, the levels of proinflammatory cytokines were unchanged, while the level of nitric oxide metabolites (NO2−+NO3−) increased to 6.5-fold that of the control. The time-course on IDM treatment indicated that, firstly, intestinal injury was induced, the NO level increased, and the hepatic Oatp1b2 and Mrp2 expression began to fall followed by an increase in plasma ALT. In conclusion, IDM-induced injury to the small intestine causes the hypofunction of hepatic Oatp1b2 and Mrp2 independently on the hepatic impairment, and NO arising from bowel injury may be one of key factors for it through the remote effect.

17 May 2024 in The Journal of Immunology
Verified
Journal Article
Closed access
TTTokiyoshi Tanegashima
Tokiyoshi Tanegashima
Masaki ShiotaMasaki Shiota
Masaki Shiota
NFNobuhiro Fujiyama
Nobuhiro Fujiyama
SNShintaro Narita
Shintaro Narita
THTomonori Habuchi
Tomonori Habuchi
MEMasatoshi Eto
Masatoshi Eto
Immune checkpoint blockade therapies are widely used for cancer treatment, including advanced renal cell carcinoma (RCC). This study aimed to investigate the impact of zygosity in HLA genes and individual HLA genotypes on the efficacy of an anti-PD-1 Ab, nivolumab, in treating advanced RCC. Patient enrollment was conducted across 23 institutions in Japan from August 19, 2019, to September 30, 2020, with follow-up concluding on March 31, 2021. HLA genotype imputation of HLA-A, B, and C, DQB1, and DRB1 loci was performed. Among 222 patients, the presence of at least one homozygosity of the HLA-II allele significantly improved the best objective response (hazard ratio, 0.34; 95% confidence interval, 0.21–0.96; p = 0.042). The HLA evolutionary divergence (HED) of the HLA-A and HLA-B loci was higher than the HLA-C (p < 0.0001 and p < 0.0001, respectively), with high HED of the HLA-B locus correlating to clinical benefits in nivolumab treatment (hazard ratio, 0.44; 95% confidence interval, 0.21–0.90; p = 0.024) and improving cancer-specific survival compared with the low group (p = 0.0202). Additionally, high HED of the HLA-B locus was correlated with the number of infiltrated CD8+ cells in the tumor microenvironment (correlation coefficient, 0.4042). These findings indicate that the diversity of the HLA-B locus plays a significant role in the anti-tumor effect of nivolumab treatment in advanced RCC, potentially offering insights for improved risk stratification in nivolumab treatment and leading to better medical management of advanced RCC.

21 May 2026 in Scientific Reports
Verified
Journal Article
Open access
NFNobuhiro Fujiyama
Nobuhiro Fujiyama
AKAyuto Kodama
Ayuto Kodama
MSMarco M. Z. Sharkawi
Marco M. Z. Sharkawi
KMKazuo Mishima
Kazuo Mishima
HOHidetaka Ota
Hidetaka Ota
This study evaluated the utility of a smartphone-based walking-speed application for early mild cognitive impairment (MCI) screening under every day, real-world conditions. Community-dwelling adults aged ≥ 65 years were recruited from dementia prevention activities in Yokote City, Akita Prefecture, (entry period: October 2022-January 2023; assessment period: October 2022-May 2023). A walking-speed app was installed on each participant's personal smartphone, and outdoor, GPS-enabled daily walking speed was continuously recorded. At baseline, we collected clinical and physical measures, including infrared-measured 5-meter usual walking speed (UWS), the National Center for Geriatrics and Gerontology-Functional Assessment Tool (NCGG-FAT), and the Touch Panel-type Dementia Assessment Scale (TDAS). Of 123 enrollees, evaluable walking-speed data were obtained from 115. To reduce noise in the raw dataset, segments meeting predefined criteria for walking distance, walking time, walking speed, steps per unit time, and step length were extracted and defined as unconscious walking speed (UcWS). In time-stratified analyses evaluating its potential as a proxy for UWS, UcWS showed a positive correlation with UWS (maximum r = 0.47). Compared with clinical measures, UcWS was significantly slower in MCI positive participants (median comparison p = 0.018; mean comparison p = 0.011), supporting UWS substitutability. Using walking-duration stratification, we identified a foundational UcWS analytic framework that may serve as a practical proxy for UWS using readily obtainable smartphone-based GPS and accelerometer data. Reduced UcWS was also associated with MCI screening positivity, supporting its potential utility as a scalable real-world digital biomarker for early cognitive decline research.

21 October 2023 in Clinical and Experimental Nephrology
Verified
Journal Article
Open access
PDF file
NFNobuhiro Fujiyama
Nobuhiro Fujiyama
MTMasayuki Tasaki
Masayuki Tasaki
HHHiroshi Harada
Hiroshi Harada
KTKoichi Tsutahara
Koichi Tsutahara
AMAkihiko Matsumoto
Akihiko Matsumoto
JTJapanese Post-kidney Transplant TMA Support Team
Japanese Post-kidney Transplant TMA Support Team

27 August 2023 in Clinical and Experimental Nephrology
Verified
Journal Article
Closed access
PDF file
NFNobuhiro Fujiyama
Nobuhiro Fujiyama
MTMasayuki Tasaki
Masayuki Tasaki
HHHiroshi Harada
Hiroshi Harada
KTKoichi Tsutahara
Koichi Tsutahara
AMAkihiko Matsumoto
Akihiko Matsumoto
JTJapanese Post-kidney Transplant TMA Support Team
Japanese Post-kidney Transplant TMA Support Team

Verified
Journal Article
Open access
PDF file
TSTakuro Saito
Takuro Saito
MSMitsuru Saito
Mitsuru Saito
RYRyohei Yamamoto
Ryohei Yamamoto
SSSagehashi Sagehashi
Sagehashi Sagehashi
YAYu Aoyama
Yu Aoyama
THTomonori Habuchi
Tomonori Habuchi
Chronic allograft dysfunction, driven by interstitial fibrosis and tubular atrophy, remains a major cause of long-term renal allograft loss. Everolimus (EVR), a mammalian target of rapamycin (mTOR) inhibitor, may reduce fibrosis through antifibrotic effects and calcineurin inhibitor minimization. This study aimed to evaluate the impact of EVR-involving immunosuppression on renal allograft fibrosis and to identify predictors of fibrotic progression. A total of 104 living-donor kidney transplant recipients transplanted between 2011 and 2017 were retrospectively analyzed (EVR, n = 61; non-EVR, n = 43). Interstitial fibrosis was quantified in protocol biopsies using digital image analysis. Phosphorylation of the mTOR-signaling proteins p70 ribosomal S6 kinase and eukaryotic translation initiation factor 4E-binding protein 1 was assessed using a semiquantitative immunoreactive score. Multivariable regression analyses identified independent predictors of fibrotic progression. Cytomegalovirus infection was less frequent in the EVR group, whereas acute rejection, graft function, and graft survival were comparable between groups. At 1-year posttransplantation, interstitial fibrosis was significantly lower in the EVR group. EVR significantly suppressed p-4EBP1 phosphorylation and effectively modulated the mTOR-signaling pathway. Multivariable analysis identified the absence of EVR therapy as an independent predictor of accelerated fibrosis. EVR-involving immunosuppression attenuated renal interstitial fibrosis, likely through suppression of mTOR-signaling.